Mineral supplement

Heme Iron Bisglycinate

Heme Iron Bisglycinate, as the app describes it, is the ferrous bisglycinate chelate Ferrochel, whose iron absorption was about twice that of ferrous sulfate in five absorption experiments in 74 subjects, with ferrochel added to breakfast breads.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Heme Iron Bisglycinate after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

The app lists Heme Iron Bisglycinate as an oral mineral supplement, and its notes describe it as iron bisglycinate (Ferrochel), a chelated form of iron. Fischer and colleagues (Nutrition Reviews, 2023) describe ferrous bisglycinate as "an amino acid iron chelate that has at least 2-fold higher bioavailability than conventional iron salts and has been associated with fewer adverse GI side effects".2

The word "heme" in the app's name points to a different supplement type in the sources. Bah and colleagues (American Journal of Clinical Nutrition, 2025) describe heme iron polypeptide (HIP) as "an alternative form of supplemental iron with a distinct absorption pathway".3 Nagaraju and colleagues (BMC Nephrology, 2013) write that "HIP is produced by hydrolysis of bovine hemoglobin".4 Searches of PubMed and ClinicalTrials.gov on 16 November 2026 for "heme iron bisglycinate" returned one PubMed record, a 1999 safety evaluation of ferrous bisglycinate chelate, and no registry entry, so no study of a product combining heme iron and bisglycinate was identified.5

The app grades the evidence as strong, while the 2023 meta-analysis rated the certainty of its hemoglobin and ferritin results as "very low" and its authors wrote that "there is little confidence in the pooled effect estimate of ferrous bisglycinate on adverse GI side effects".2

The review authors write that "ferrous bisglycinate chelate is not sequestered by iron absorption inhibitors, such as phytates, found in cereal-based foods", and that the chelate "is thought to be better absorbed in the intestinal mucosal cells, thereby reducing adverse GI side effects".2 Layrisse and colleagues (Journal of Nutrition, 2000) reported that "Ferrochel partially prevented the inhibitory effect of phytates".1 Bovell-Benjamin and colleagues (American Journal of Clinical Nutrition, 2000) concluded that "Absorption of iron from bisglycinate and trisglycinate is regulated normally by iron status", with absorption "strongly inversely related to serum ferritin".6

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
25%
Typical dose
18–25 mg/day
Route
Oral
Time to peak
~4 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~6 hNo half-life, clearance or concentration-time figure for ferrous bisglycinate or heme iron appears in the sources read.
Bioavailability25%Iron absorption from ferrochel was about twice that from ferrous sulfate in 74 subjects (Layrisse 2000).1 In 10 iron-sufficient men eating whole-maize porridge, geometric mean absorption was 6.0% from ferrous bisglycinate and 1.7% from ferrous sulfate, and across 23 subjects with a range of iron statuses it was 9.1% from 3 mg of bisglycinate iron (Bovell-Benjamin 2000).6 University of British Columbia investigators describe a "2-4x higher bioavailability than ferrous sulfate" in a registry entry.7 The app's notes give about 25% with food against about 10% for ferrous sulfate, figures that none of the sources read gives.
Time to peak~4 hNot reported in the sources read.

Food and other interactions

The app's notes flag coffee, tea and calcium as interacting with absorption. In the ferrochel trial, "American-type coffee did not modify iron absorption significantly, whereas both espresso-type coffee and tea reduced iron absorption from ferrochel by 50%".1 Hurrell and colleagues (British Journal of Nutrition, 1999) reported inhibition of iron absorption from a bread meal by black tea of 79-94%; the record describes non-haem iron and does not name bisglycinate.8 Lynch's review (Nutrition Research Reviews, 2000) reports that "In single-meal human absorption studies, both haem- and non-haem-Fe absorption was inhibited by Ca supplements and by dairy products", and that "The results of most multiple-meal human studies suggest that Ca supplementation will have only a small effect on Fe absorption unless habitual Ca consumption is very low".9 In 54 nonpregnant women given radioactive iron tracers on an empty stomach, Gaitán and colleagues (Journal of Nutrition, 2011) reported that "Calcium doses ≥1000 mg diminished nonheme iron absorption by an average of 49.6%" for 5 mg of iron as ferrous sulfate, and that "A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%"; the calcium was given as calcium chloride and bisglycinate was not tested.10

4

Human studies

Searches on 16 November 2026 returned 83 PubMed records for "iron bisglycinate" and 8 ClinicalTrials.gov studies for "ferrous bisglycinate"; titles were screened, and the table lists the randomized comparisons and absorption studies read in detail, with two heme iron polypeptide trials marked as such.

Table 4.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Fischer and colleagues, Nutrition Reviews 20232Systematic review and meta-analysis of randomized trials, funded by a University of British Columbia faculty17 trials; pooled analyses in pregnant women (9) and children (4)Ferrous bisglycinate against other iron supplements, 4 to 20 weeksPregnant women: hemoglobin higher (SMD 0.54 g/dL; 95% CI 0.15-0.94), but nonsignificant in a sensitivity analysis removing trials at high or unclear risk of bias (SMD 0.53 g/dL; 95% CI -0.04, 1.11); fewer GI adverse events (IRR 0.36; 95% CI 0.17-0.76), with little confidence in the GI estimate; children: no significant differences; certainty very low
Milman and colleagues, Journal of Perinatal Medicine 201411Randomized, double-blind, intention-to-treat80 healthy ethnic Danish pregnant womenFerrous bisglycinate 25 mg elemental iron/day (n=40) or ferrous sulfate 50 mg (n=40), from 15 to 19 weeks of gestation to deliveryIron deficiency and anemia frequencies low and not significantly different; GI complaints lower with bisglycinate (P=0.001)
Milman and Bergholt, Journal of Pregnancy 202412Analysis of GI complaints from two randomized, double-blind studies; no placebo group404 women (Gentofte study, fumarate) and 78 women (Naestved study, bisglycinate and sulphate)Naestved: bisglycinate 25 mg or sulphate 50 mg elemental iron/day, between meals; Gentofte: fumarate 20, 40, 60 or 80 mg/dayBlack stools in 8% (bisglycinate 25 mg), 22% (fumarate 40 mg) and 31% (sulphate 50 mg); no woman had GI complaints needing a dose change, a formula change or discontinuation
Fischer and colleagues, Journal of Nutrition 202313,7Double-blind, placebo-controlled noninferiority trial in Cambodia480 nonpregnant women aged 18-45 y; baseline anemia 17%, iron deficiency 6%18 mg ferrous bisglycinate, 60 mg ferrous sulfate or placebo; 12 weeksAdjusted mean ferritin difference between iron groups 14.6 μg/L (95% CI 7.6, 21.6) against a noninferiority margin of 20 μg/L; mean 99 (sulfate), 84 (bisglycinate), 78 (placebo) μg/L; the authors concluded bisglycinate was not as effective as sulfate for ferritin; no difference in fecal calprotectin or enteropathogen detection
Layrisse and colleagues, Journal of Nutrition 20001Five absorption experiments with ferrochel added to breakfast breads, compared with ferrous sulfate or iron-EDTA74 subjectsFortified breakfast breads; the PubMed record gives no iron doseAbsorption from ferrochel about twice that from ferrous sulfate; espresso-type coffee and tea reduced ferrochel absorption by 50%, American-type coffee did not change it significantly
Bovell-Benjamin and colleagues, American Journal of Clinical Nutrition 20006Radioisotope absorption studies in whole-maize porridge and water10 iron-sufficient men (study 1) and 23 subjects with a range of iron statuses (study 2)Study 2: 3 mg of iron as bisglycinate, ascorbate or trisglycinateGeometric mean absorption 6.0% from bisglycinate against 1.7% from ferrous sulfate (study 1A); 9.1% from bisglycinate in study 2, inversely related to serum ferritin
Albion, registry entry NCT02128971, 201414Randomized, double-blind, parallel, six arms; industry sponsorEnrollment count in the entry: 108Ferrochel capsule 90 mg once daily for 30 days, against four other iron products and placeboStatus UNKNOWN (last known status RECRUITING); no results in the entry
Bah and colleagues, American Journal of Clinical Nutrition 2025 (heme iron polypeptide, not bisglycinate)3Randomized trial of HIP against ferrous sulfate, Gambia208 anemic infants aged 6-12 months10 mg elemental iron/day as HIP or ferrous sulfate; 84 daysHemoglobin and ferritin improved with no difference between treatments; anemia 84.6% to 47.1% (HIP) and 83.7% to 46.2% (sulfate); no group differences in adverse events
Nagaraju and colleagues, BMC Nephrology 2013 (heme iron polypeptide)4Randomized, single-blind trial of oral HIP against intravenous iron sucrose40 patients with non-dialysis chronic kidney disease and iron deficiency anemia; 14 of 18 (HIP) and 19 of 22 (iron sucrose) completed per protocolHIP 11 mg orally 3 times per day or iron sucrose 200 mg intravenously monthly; 6 monthsHemoglobin 117 g/L (HIP) and 113 g/L (iron sucrose), p = 0.37; serum ferritin higher with iron sucrose, 85.5 against 244 μg/L, p = 0.004; overall adverse events not different, with 3 HIP patients discontinuing for new or worsening abdominal cramps and symptomatic hypotension in 3 iron sucrose patients during infusion

Deeper analysis: the 2023 meta-analysis of ferrous bisglycinate trials

Fischer, Cherian, Bone and Karakochuk at the University of British Columbia searched databases and grey literature up to 17 July 2020 and identified 17 randomized trials of at least 4 weeks of supplementation that reported hemoglobin or ferritin.2 The comparators were other iron supplements; the authors note that "ferrous fumarate was commonly used as a comparison with ferrous bisglycinate", and in the pooled children's analysis three trials used ferrous sulfate and one polymaltose iron as the comparator.2 In pregnant women, 4 to 20 weeks of ferrous bisglycinate gave higher hemoglobin (SMD 0.54 g/dL; 95% CI 0.15-0.94) and fewer reported GI adverse events (IRR 0.36; 95% CI 0.17-0.76), with "a non-significant trend for higher ferritin"; in children "No significant differences in hemoglobin or ferritin concentrations were detected".2 A sensitivity analysis that removed 5 pregnancy trials at high or unclear risk of bias gave a hemoglobin SMD of 0.53 g/dL (95% CI -0.04, 1.11), a nonsignificant difference that the authors describe as limited by a small number of studies (n = 4).2 A footnote reports that "Ten trials showed no differences in hemoglobin concentrations between iron groups after the intervention", and four of the 17 trials had an overall low risk of bias, 7 unclear and 6 high.2 The authors also report that "Evidence of publication bias was detected with the visual inspection of funnel plots for both hemoglobin and ferritin concentration outcome measures in pregnant and children".2 Stated limitations include that "studies evaluating ferrous bisglycinate fortification were omitted", that "the review was not positioned to evaluate the optimal dose, frequency, or duration of ferrous bisglycinate supplementation", and that "Not all trials included in this review used inflammation-adjusted ferritin concentrations".2 Funding came from the Faculty of Land and Food Systems at the University of British Columbia, and the authors state: "The authors declare no relevant interests to declare."2

Deeper analysis: the Danish pregnancy trials

Milman and colleagues reported a randomized, double-blind, intention-to-treat trial in the Journal of Perinatal Medicine in 2014, comparing ferrous bisglycinate 25 mg and ferrous sulfate 50 mg of elemental iron a day in 80 healthy ethnic Danish pregnant women, 40 in each group.11 The main outcomes were occurrence of iron deficiency and iron deficiency anemia, which "were low and not significantly different in the two iron groups", while GI complaints were lower with bisglycinate (P=0.001).11 Newborn weight was slightly higher in the bisglycinate than the sulfate group (3601±517 g against 3395±426 g, P=0.09).11 The authors concluded that "In the prevention of ID and IDA, ferrous bisglycinate was not inferior to ferrous sulfate".11 The PubMed record carries no funding statement, conflict statement or limitations section.11 Milman and Bergholt, at Herlev and Gentofte University Hospital, later reported gastrointestinal complaints from "two randomized, double-blind studies" in the Journal of Pregnancy in 2024.12 The Naestved study there used the same two doses and the same gestational window as the 2014 trial, with 78 women; the records read do not say whether the participants overlap.12 Black stools occurred in 8% with bisglycinate 25 mg and 31% with sulphate 50 mg in the Naestved study and in 22% with fumarate 40 mg in the separate Gentofte study, against 9.3% at inclusion in the combined series, and the authors report that bisglycinate "is associated with significantly fewer GI complaints" than the other two.12 They also write that "due to the lack of a placebo group, it is not possible to determine whether these differences may be caused by possible side effects of the iron formulas or are due to the normal physiological variations in GI complaints occurring during pregnancy".12 The Naestved study was supported by grants including Pharmovital ApS and Vitalkost AS, and the 2024 analysis by an unrestricted grant from Pharmovital ApS; the authors state that "The funding sources were not involved in the study design, data collection, analysis and interpretation, manuscript writing, or the decision to submit the article for publication" and declare no conflicts of interest.12

Deeper analysis: the Cambodian women trial

Fischer, Pei, Elango, Hou, Goldfarb and Karakochuk (University of British Columbia, BC Children's Hospital Research Institute and Helen Keller International) reported a double-blind, placebo-controlled noninferiority trial in the Journal of Nutrition in 2023.13 It randomized 480 nonpregnant women aged 18 to 45 years to 60 mg ferrous sulfate, 18 mg ferrous bisglycinate or placebo for 12 weeks, in a population with baseline anemia of 17% and iron deficiency of 6%.13 The primary outcome was ferritin at 12 weeks against a noninferiority margin of 20 μg/L; the adjusted mean difference between the iron groups was 14.6 μg/L (95% CI 7.6, 21.6), with mean ferritin of 99 μg/L with sulfate, 84 with bisglycinate and 78 with placebo.13 The authors concluded that 18 mg ferrous bisglycinate "was not as effective as ferrous sulfate (60-mg) in increasing ferritin concentrations and did not differentially influence biomarkers of gut health in this predominantly iron-replete population of Cambodian women".13 Secondary gut outcomes showed "No differences in fecal calprotectin concentrations or enteropathogen detection", with enteropathogens assessed in a random subset of 100 women.13 The registry entry names the University of British Columbia as lead sponsor and states that the tablets were made by Natural Factors, which handled allocation concealment.7 The PubMed record lists the grant "CIHR ID400771" and no conflict statement; the authors' own limitations and any ties to the tablet maker are not in that record, and the same group wrote the 2023 meta-analysis.13

Deeper analysis: the ferrochel and maize absorption studies

Layrisse and colleagues measured the absorption of ferrochel added to breads, compared with the same breakfast enriched with ferrous sulfate or iron-EDTA, in 74 subjects across five experiments, and reported that absorption from ferrochel was about twice that from ferrous sulfate.1 The authors conclude that ferrochel "is a suitable compound for food fortification"; the PubMed record gives no funding statement, conflict statement or limitations.1 Bovell-Benjamin and colleagues at the University of California, Davis, gave 10 iron-sufficient men whole-maize porridge labelled with isotopes; geometric mean absorption was 6.0% (range 2.6-13.6%) from ferrous bisglycinate, "4 times higher than that from ferrous sulfate".6 The PubMed record lists "Research Support, Non-U.S. Gov't" and gives no limitations or conflict statement.6

Deeper analysis: heme iron polypeptide in Gambian infants

Bah and colleagues (Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine and Wageningen University) randomized 208 anemic infants aged 6 to 12 months to 84 days of directly observed daily supplementation with 10 mg of elemental iron as HIP or ferrous sulfate.3 This trial tested heme iron polypeptide, not bisglycinate, so its result is not a result for the app's compound.3 The primary outcomes "both improved by day 84 with no difference between treatments", and the authors conclude "There is no benefit of HIP on the primary end points of hemoglobin and ferritin".3 Among secondary measures, infants given HIP had higher serum iron (by 48.4%; 95% CI 15.4%, 91.0%), and a post hoc analysis showed a greater effect on inflammation-adjusted ferritin (by 22.9%; 95% CI 5.6%, 43.1%).3 There were 193 adverse events, 103 with ferrous sulfate and 90 with HIP, none considered related to the interventions, and no deaths during the study or the 2-week follow-up.3 The authors call it a "small proof-of-principle trial" that "was not designed to give definitive reassurance on safety", and list limitations including that they "did not assess other micronutrient deficiencies" and that "the intervention duration may have been too short to observe the full potential improvements in Hb".3 Funding came from the UK Medical Research Council (MR/R023360/1) and the UK Department for International Development through the MRC/DFID Concordat; the authors state that the funders "had no role in the design and conduct of the study" and report no conflict of interest.3 In the 40-patient chronic kidney disease trial of HIP against intravenous iron sucrose, the authors wrote that "We had limited ability to detect a difference in Hgb values due to our small sample size (power 0.56)" and that none of them had conflicts of interest to declare.4

5

Doses reported in studies and on labels

The app's typical dose is 18 to 25 mg a day; the rows below give the elemental iron amounts in the trials read and on the one product label read.

Table 5.1Doses reported in studies and on labels4 rows
SourceProduct and doseComparatorPopulation and duration
Fischer 202313Ferrous bisglycinate 18 mgFerrous sulfate 60 mg; placebo480 nonpregnant women, 12 weeks
Milman 201411Ferrous bisglycinate 25 mg elemental iron/dayFerrous sulfate 50 mg elemental iron/day80 pregnant women, from 15 to 19 weeks of gestation to delivery
Milman and Bergholt 2024, Naestved study12Ferrous bisglycinate 25 mg elemental iron/day between mealsFerrous sulphate 50 mg/day; fumarate 20 to 80 mg/day in a separate study of 404 women78 women, from 15 to 19 weeks of gestation to delivery
MaxFe tablet label, Pronova Corporation15160 mg of iron per caplet from carbonyl iron and ferrous bisglycinate chelate (Ferrochel), with vitamin C, folate, B12, biotin and zinc; the label gives no split between the two iron forms and states "One caplet daily with or without food", or as recommended by a healthcare providerNot applicableLabel indication: "improving the nutritional status of patients with iron deficiency"; "not for use in children under 12 years of age"

The 2023 meta-analysis found fewer reported GI adverse events with ferrous bisglycinate than with other iron supplements in pregnant women (IRR 0.36; 95% CI 0.17-0.76), while stating that "there is little confidence in the pooled effect estimate of ferrous bisglycinate on adverse GI side effects" because of funnel plot asymmetry and heterogeneity.2 In the 2024 Danish analysis, black stools occurred in 8% on bisglycinate 25 mg and 31% on sulphate 50 mg in the Naestved study and in 22% on fumarate 40 mg in the separate Gentofte study, against 9.3% at inclusion in the combined series, with no placebo group.12 The MaxFe label for a product containing carbonyl iron and ferrous bisglycinate chelate carries the warning "Accidental overdose of iron-containing products is leading a cause of fatal poisoning in children under 6 years of age" and lists "Patients with hemochromatosis and hemosiderosis" among those the product is not for.15 In rats, Jeppsen and Borzelleca (Food and Chemical Toxicology, 1999) reported an acute oral LD50 of 2800 mg/kg body weight for ferrous bisglycinate and a no-observed-adverse-effect level of 500 mg/kg body weight a day, "the highest dose tested"; the first author's affiliation is Albion Laboratories, which holds the Ferrochel trademark.5,15

7

Bloodwork and markers

The app lists ferritin, hemoglobin and TIBC as markers to monitor. The 2023 meta-analysis took hemoglobin and ferritin as its primary outcomes and GI adverse events as its secondary outcome.2 It notes that "ferritin is an acute-phase protein known to be affected by inflammation status", and that not all included trials adjusted for it.2 The Gambian heme iron polypeptide trial also measured serum iron, transferrin saturation, soluble transferrin receptor and unsaturated iron-binding capacity.3 None of the sources read reports total iron-binding capacity (TIBC) as an outcome for ferrous bisglycinate.

8

Regulatory and anti-doping status

The World Anti-Doping Agency's 2026 Prohibited List states that it "shall come into effect on 1 January 2026", and the text read contains no entry naming iron, ferrous compounds or heme iron.16 The one US label read, for the multi-ingredient MaxFe tablet, describes it as "a multivitamin / multimineral dietary supplement" and carries the statement "This statement has not been evaluated by the FDA."15

9

Storage and handling

Sources in this part

  1. 15Pronova Corporation, 2023

The MaxFe label, for a multi-ingredient tablet containing ferrous bisglycinate chelate, states "Store at controlled room temperature 59°-86°F."15

None of the sources read gives a half-life, a time to peak or a concentration-time profile for ferrous bisglycinate or heme iron, so the app's 6 hours and 4 hours have no figure from the sources beside them. The app's 25% bioavailability and its 10% figure for ferrous sulfate are not reported in the sources read, which give 6.0%, 1.7% and 9.1% under the conditions described above.6 The meta-analysis authors state that "More trials are needed to assess the efficacy of ferrous bisglycinate against other iron supplements in other populations", and the 2023 Cambodian trial found the 18 mg bisglycinate arm "was not as effective as ferrous sulfate (60-mg) in increasing ferritin concentrations" in a mostly iron-replete group.2,13 Hallberg and Hulthén titled a 2000 letter in the American Journal of Clinical Nutrition "No advantage of using ferrous bisglycinate as an iron fortificant"; the PubMed record holds no summary text for it, and its argument was not read.17

What is the half-life of heme iron bisglycinate?

The app lists about 6 hours, and none of the sources read reports a half-life for ferrous bisglycinate or heme iron.

Is heme iron bisglycinate the same as heme iron polypeptide?

The sources read describe them as separate forms of supplemental iron: ferrous bisglycinate is "an amino acid iron chelate", while heme iron polypeptide is "produced by hydrolysis of bovine hemoglobin".2,4

How well is iron bisglycinate absorbed compared with ferrous sulfate?

In five experiments with 74 subjects, with ferrochel added to breakfast breads, absorption from ferrochel was about twice that from ferrous sulfate.1 In 10 iron-sufficient men eating whole-maize porridge, geometric mean absorption was 6.0% from ferrous bisglycinate against 1.7% from ferrous sulfate.6 The app lists 25% bioavailability, a figure none of the sources read gives.

Does iron bisglycinate cause fewer GI side effects than ferrous sulfate?

In pregnant women a meta-analysis comparing ferrous bisglycinate with other iron supplements, not only ferrous sulfate, reported fewer GI adverse events (IRR 0.36; 95% CI 0.17-0.76), though its authors have "little confidence in the pooled effect estimate".2 A Danish trial of 80 pregnant women reported lower GI complaint frequency with bisglycinate 25 mg than sulfate 50 mg (P=0.001).11

Did 18 mg of ferrous bisglycinate raise ferritin as much as 60 mg of ferrous sulfate?

In a 12-week trial of 480 Cambodian women, mean ferritin was 84 μg/L with 18 mg ferrous bisglycinate and 99 μg/L with 60 mg ferrous sulfate, and the authors judged the bisglycinate "not as effective" for ferritin.13

Is heme iron bisglycinate banned by WADA?

The 2026 Prohibited List text read contains no entry naming iron, ferrous compounds or heme iron.16

Do coffee and tea reduce iron absorption from iron bisglycinate?

In one trial, espresso-type coffee and tea each reduced iron absorption from ferrochel by 50%, while American-type coffee did not modify absorption significantly.1

How strong is the evidence for iron bisglycinate?

The app grades the evidence as strong, while the 2023 meta-analysis rated the certainty of its hemoglobin and ferritin results as very low.2

13

References

  1. Layrisse M, et al. Iron bioavailability in humans from breakfasts enriched with iron bis-glycine chelate, phytates and polyphenols. J Nutr 2000. PMID 10958812
  2. Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2023. PMID 36728680
  3. Bah M, Verhoef H, Okoh E, et al. Heme iron compared with ferrous iron salts to treat iron deficiency anemia in Gambian children: a randomized controlled trial. Am J Clin Nutr 2025. PMID 40803493
  4. Nagaraju SP, Cohn A, Akbari A, Davis JL, Zimmerman DL. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol 2013. PMID 23514036
  5. Jeppsen RB, Borzelleca JF. Safety evaluation of ferrous bisglycinate chelate. Food Chem Toxicol 1999. PMID 10496373
  6. Bovell-Benjamin AC, Viteri FE, Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr 2000. PMID 10837299
  7. ClinicalTrials.gov. NCT04017598. Potential Harms of Untargeted Iron Supplementation in Cambodia Where Iron Deficiency is Not the Cause of Anemia. University of British Columbia. NCT04017598
  8. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr 1999. PMID 10999016
  9. Lynch SR. The effect of calcium on iron absorption. Nutr Res Rev 2000. PMID 19087437
  10. Gaitán D, Flores S, Saavedra P, et al. Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women. J Nutr 2011. PMID 21795430
  11. Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med 2014. PMID 24152889
  12. Milman NT, Bergholt T. Low-Dose Prophylactic Oral Iron Supplementation (Ferrous Fumarate, Ferrous Bisglycinate, and Ferrous Sulphate) in Pregnancy Is Not Associated With Clinically Significant Gastrointestinal Complaints: Results From Two Randomized Studies. J Pregnancy 2024. PMID 39582678
  13. Fischer JAJ, Pei LX, Elango R, Hou K, Goldfarb DM, Karakochuk CD. Is a Lower Dose of More Bioavailable Iron (18-mg Ferrous Bisglycinate) Noninferior to 60-mg Ferrous Sulfate in Increasing Ferritin Concentrations While Reducing Gut Inflammation and Enteropathogen Detection in Cambodian Women? A Randomized Controlled Noninferiority Trial. J Nutr 2023. PMID 37271416
  14. ClinicalTrials.gov. NCT02128971. A Study to Compare the Gastrointestinal Tolerability of Ferrochel, Sumalate, Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo. Albion. NCT02128971
  15. Pronova Corporation. MaxFe (multi-ingredient tablet with carbonyl iron and ferrous bisglycinate chelate). US label, DailyMed version 2, 2023. DailyMed label
  16. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  17. Hallberg L, Hulthén L. No advantage of using ferrous bisglycinate as an iron fortificant. Am J Clin Nutr 2000. PMID 11101499